Advertisement

sglt2 inhibitors

You have accessRestricted Access
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria
Meg Jardine, Zien Zhou, Hiddo J. Lambers Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal, George L. Bakris, Christopher P. Cannon, David M. Charytan, Tom Greene, Adeera Levin, Jing-Wei Li, Brendon L. Neuen, Bruce Neal, Richard Oh, Megumi Oshima, Carol Pollock, David C. Wheeler, Dick de Zeeuw, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey and Vlado Perkovic

CJASN February 2021, CJN.15260920; DOI: https://doi.org/10.2215/CJN.15260920

Add to Selected Citations
You have accessRestricted Access
SGLT2 Inhibitors across the Spectrum of Severity of CKD
Ali Ziaolhagh and Christos Argyropoulos

CJASN October 2020, 15 (10) 1386-1388; DOI: https://doi.org/10.2215/CJN.13430820

Add to Selected Citations
You have accessRestricted Access
Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology
Daniel Edmonston and Myles Wolf

CJASN January 2019, 14 (1) 7-9; DOI: https://doi.org/10.2215/CJN.13801118

Add to Selected Citations
Open Access
Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Roberto Pecoits-Filho and Vlado Perkovic

CJASN February 2018, 13 (2) 318-320; DOI: https://doi.org/10.2215/CJN.07680717

Add to Selected Citations